This is the second in a series of videos I’m doing where I answer questions about the stem cell field. You can see the Episode 1 video here. Today I tackle more questions on the stem cell field. If you have more stem cell questions, let me know and I’ll try to answer them next time. […]
Q&A video with Paul Episode 2: stem cell & CRISPR questions answered Read More »
Each year I make a list of predictions for the stem cell and regenerative medicine field for the coming new year. Later in this post I list my top 20 stem cell predictions for 2017. In looking at my past predictions I realized this will now be my 7th year doing stem cell/regenerative medicine yearly predictions.
Stem Cell Predictions for 2017 Read More »
I try to catch up on my science reading over the weekends and evenings. Here’s my recommended weekend reading on stem cells & science. Did I miss anything especially cool? Let me know in the comments. Direct reprogramming of skin cells into insulin-producing cells. I love direct reprogramming. Healios and Athersys Enter Into Regenerative Medicine Partnership.
Recommended weekend reading on stem cells & science Read More »
To get from point A of a stem cell discovery to point B of a patient actually receiving a treatment based on that discovery is a long and non-linear road, which requires biotech company research. Stem cell biotech companies including publicly traded companies are an integral part of the field making that journey. How those
Tale of 7 stem cell biotech stock woes Read More »
The stem cell company Stemedica has made a name for itself in the media lately through hockey legend Gordie Howe, who received a non-FDA approved stem cell “treatment” in Mexico via Stemedica and its partner, Novastem. Howe, known as Mr. Hockey, had several strokes in late 2014 and his health was declining. Stemedica and Novastem
Olbermann Puff Interview on Stemedica & Gordie Howe Read More »
What are the most interesting questions for the stem cell field in 2014 right now? What’s on your mind? I’m not going to give this deep thought, but rather just list those questions bouncing around at the moment in no particular order. You can see a lot of translational/clinical things are on my mind. I’ve
Key questions for stem cell field bouncing around on a Friday morning Read More »
The below is an excerpt from my book, Stem Cells: An Insider’s Guide. I hope you enjoy this excerpt and the book, which I think is a really good deal at under $27 paperback or under $17 for E-book version. Having our innovation and ethics too In the stem cell field you can have it
Book Excerpt: Stem Cell For-Profit Good Citizen Biotechs Read More »
The Australian stem cell biotech Mesoblast (MSB) has reportedly reached a deal with the American stem cell biotech Osiris (OSIR) to buy Osiris’ mesenchymal stem cell (MSC) unit. This is a big development in the MSC field. Osiris and Mesoblast are two major players in this particular subfield of the stem cell world so this deal,
Mesoblast (MSB) buys Osiris (OSIR) stem cell unit Read More »
Over at the Harvard Law “Bill of Health” blog, Mary Ann Chirba and Alice A. Nobel posted a piece entitled “Our Bodies, Our Cells” a few days ago that has generated a lot of discussion about FDA regulation of stem cell interventions. Their piece really has two parts. In the first part they go through
My response to ‘Our Bodies, Our Cells’ Harvard post on deregulation Read More »
I’ve been fortunate to interview some of the greats in the stem cell field for this blog and host debates between key players. Please note that just because I have interviewed folks does not mean I agree with them or that they agree with me. The point is to establish dialogue on key issues. As
Interviews with leaders and top players in the stem cell field Read More »